CD5 is a surface glycoprotein present on peripheral T cells (>95%) and B-cell chronic lymphocytic leukaemia cells that binds CD72. CD5 has utility for the monitoring of T-cell numbers in peripheral blood and the identification of leukaemias of T cell origin. Absence of the CD5 marker on childhood ALL cells is associated with a more favourable prognosis.
| Inventor | Institute |
|---|---|
| Jacqueline Cordell | University of Oxford |
| Cat. #: | 151344 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Cancer types: | Blood cancer |
| Research Fields: | Immunology;Stem cell biology |
| Application: | FACS ; IHC ; IF ; IP ; WB |
| Target: | Leu1 (CD5) |
| Reactivity: | Human |
| Clone: | Y2/178 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD5 Molecule 2; Lymphocyte Antigen T1/Leu-1; LEU1; CD5 Antigen; T1 |
|---|---|
| Product description: | CD5 is a surface glycoprotein present on peripheral T cells (>95%) and B-cell chronic lymphocytic leukaemia cells that binds CD72. CD5 has utility for the monitoring of T-cell numbers in peripheral blood and the identification of leukaemias of T cell origin. Absence of the CD5 marker on childhood ALL cells is associated with a more favourable prognosis. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Immunogen: | Normal lymphocytes treated with PHA (phytohaemagglutinin) |
| Myeloma used: | P3/NS1/1-Ag4.1 |
| Target background: | CD5 is a surface glycoprotein present on peripheral T cells (>95%) and B-cell chronic lymphocytic leukaemia cells that binds CD72. CD5 has utility for the monitoring of T-cell numbers in peripheral blood and the identification of leukaemias of T cell origin. Absence of the CD5 marker on childhood ALL cells is associated with a more favourable prognosis. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Hassan et al. 2006. Mol Cell Biol. 26(17):6727-38. PMID: 16914752. CD6 regulates T-cell responses through activation-dependent recruitment of the positive regulator SLP-76. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151017 | Anti-MBP [R29.6] |
Key Info
Anti-MBP [R29.6]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.